About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, June 22nd, 2017

The QualityStocks
Daily Stock List


M Pharmaceutical, Inc. (MPHMF)

MoneyTV, OTC Stock Review, and PCG Advisory reported earlier on M Pharmaceutical, Inc. (MPHMF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage company, M Pharmaceutical, Inc. is developing unique technologies for obesity, weight management, as well as female health & wellness. OTCQB-listed, the Company’s dedication is to develop and commercialize its innovative drug treatments and biomedical technologies that provide the end user realistic solutions founded on the principles of reduced invasiveness and enhanced effectiveness. M Pharmaceutical has offices in Vancouver, British Columbia, and Calgary, Alberta.

The Company recently acquired C-103, a reformulation of orlistat, and assets from 40J's LLC. In addition, M Pharmaceutical is scheduled to launch its Food and Drug Administration (FDA) cleared fertility product branded as ToConceive in July 2017.

C-103 is a novel reformulation of orlistat, patented until 2030 in the United States.  Orlistat is FDA-approved for weight management. It is sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (Over-the-Counter (OTC)).  The intention of C-103 is to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events.

ToConceive is a women’s health treatment. It is supported by an FDA 510K clearance and is protected by four USPTO (United States Patent and Trademark Office) patents. ToConceive is a unique new infertility treatment. It offers hope and assistance to the millions of couples globally struggling to start a family.

In addition, M Pharmaceutical has exclusive rights to Trimeo Weight Loss Capsules. This is a biomedical technology to manage obesity and diabetes. Trimeo Weight Loss Capsules are drug free, individually controllable expandable implements. They result in a dynamic gastric volume reduction, inducing a feeling of early satiety and lessening food intake. 

Earlier this month, M Pharmaceutical announced that it recently received official USPTO (United States Patent and Trademark Office) "Notice Of Allowance" for the US Trademark of EXTRINSA, its solution for Female Sexual Dysfunction (FSD). In addition, in early June, the Company announced that Mr. Gary Stephens is joining M Pharmaceutical as its new Chief Financial Officer (CFO), effective immediately.

Mr. Stephens has a wide-ranging background in corporate finance, treasury planning and analysis, strategic planning and risk management. He also has a deep appreciation for M Pharmaceutical’s unique position propelling worldwide health and wellness. Mr. Stephens is a Certified Public Accountant. He is licensed in the states of Kentucky and Ohio.

M Pharmaceutical, Inc. (MPHMF), closed Thursday's trading session at $0.037, up 12.12%, on 50,000 volume with 2 trades. The average volume for the last 60 days is 32,738 and the stock's 52-week low/high is $0.027/$0.12.

Skkynet Cloud Systems, Inc. (SKKY)

OTC Markets Group and SmallCapVoice reported on Skkynet Cloud Systems, Inc. (SKKY), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Skkynet Cloud Systems, Inc. is an international leader in real-time cloud information systems. The Skkynet Connected Systems platform includes the award-winning SkkyHub™ service, DataHub®, WebView™, and Embedded Toolkit (ETK) software. The Company operates through a number of wholly-owned subsidiaries. These include Cogent Real-Time Systems, Inc. and Nic Corp.  Skkynet Cloud Systems is based in Mississauga, Ontario.

The Skkynet Connected Systems platform enables real-time data connectivity for industrial, embedded, and financial systems, with no programming needed. Skkynet’s customers include Microsoft, Caterpillar, Siemens, Metso, ABB, Honeywell, IBM, GE, BP, Goodyear, BASF, E·ON, Bombardier and the Bank of Canada.

The Company’s Cogent Real-Time Systems is an industrial middleware vendor. Cogent has introduced numerous innovations to its real-time data product. These include a high-speed redundancy facility and a web-based user interface providing immersive, desktop-quality graphics.  Skkynet’s Nic Corp. (Osaka, Japan) specializes in embedded hardware and software designs.

Skkynet Cloud Systems’ SkkyHub™ is a secure, end-to-end service. It makes it easy to connect and network almost any industrial system or embedded device. The Company’s DataHub® allows one to connect to multiple data sources and clients such as OPC, Modbus, TCP, ODBC, and more.

Furthermore, the Company has its Financial Vine™.  Vine™ connects to all of one’s data sources such as Bloomberg, Reuters, or one’s custom data feeds. It delivers one’s analytical results to everyone that needs to see them in Excel.

Concerning Embedded Toolkit (ETK), SkkyHub™ and DataHub® products accept Machine-to-Machine (M2M) connections from any device that is running the ETK. The ETK is a C library. It provides the building blocks to connect and communicate with the SkkyHub™ service or DataHub®, which permits any device to securely connect to the Internet of Things (IoT) in real time for remote monitoring and supervisory control.

Yesterday, Skkynet Cloud Systems announced that the Cogent DataHub successfully passed OPC interoperability testing with top brands of OPC UA servers and clients at the Asian OPC Interoperability Workshop 2017 held in Tokyo, Japan from June 14-16.  Multi-national companies participating in the event included Azbil, Emerson, Kepware, OMRON, Schneider Electric, Takebishi, Toshiba, and Yokogawa.

Mr. Paul Thomas, President of Skkynet Cloud Systems, said, “OPC UA is a sophisticated and complex data communications protocol. Adhering to the spec is one thing, but the real proof of compatibility is to test the clients and servers from different manufacturers against each other. The fact that the Cogent DataHub communicates seamlessly with all of the other leading products means that it can be used in virtually any OPC UA system.”

Skkynet Cloud Systems, Inc. (SKKY), closed Thursday's trading session at $0.252, down 71.36%, on 515 volume with 2 trades. The average volume for the last 60 days is 1,775 and the stock's 52-week low/high is $0.4299/$0.96.

TechPrecision Corp. (TPCS)

Marketbeat, TopPennyStockMovers, Zacks, StreetInsider, Energy and Capital, Wealth Daily, FeedBlitz, SmallCapVoice, BullRally, HotOTC, CoolPennyStocks, PennyStockVille, Stock Rich, MadPennyStocks, and Stock Market News Alert reported earlier on TechPrecision Corp. (TPCS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TechPrecision Corp., by way of its wholly-owned subsidiaries, Wuxi Critical Mechanical Components Co., Ltd., and Ranor, Inc., is an industry leading manufacturer of precision, large-scale fabricated and machined metal components and tested systems. The Company’s objective is to be an end-to-end international service provider to its customers through furnishing customized and integrated turn-key solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing.

Established in 2006, TechPrecision has its corporate headquarters in Westminster, Massachusetts. Its subsidiary companies have facilities located in the U.S. and China. TechPrecision lists on the OTC Markets Group’s OTCQB.

The Company’s products are used in the alternative energy, medical, nuclear, defense, and precision industrial, aerospace, and naval/maritime markets, among others. The design of its Wuxi Critical Mechanical Components (CMC) subsidiary is to meet the increasing global demand for an experienced, knowledgeable machining and distribution center in Asia, providing large-scale component fabrication solutions for the region's solar and wind power challenges.

CMC (founded in 2010) employs one of the largest forges in the industry. CMC’s capabilities include Forging; Fabrication; Machining; Inspection; Assembly & Finishing, as well as Quality Assurance. CMC serves the Solar/LED; Wind; Nuclear; Clean Technology, Medical; and General Industrial industries.
TechPrecision’s Ranor subsidiary (founded in 1956) specializes in large-scale, precision component fabrication for the Clean Technology, Energy, Medical, Aerospace, and Defense sectors. Ranor’s capabilities encompass Production Control; Engineering; Processing; Fabrication; Machining; Assembly & Finishing; Quality Assurance, and NDE & Inspection.

TechPrecision has the fabrication capacity to see a client’s large-scale components through from initial processing to final finishing and assembly. This eliminates the requirement for outside servicing and helps ensure lower costs.

Recently, TechPrecision announced that, effective March 31, 2017, Mr. Leonard M. Anthony, Mr. Phillip A. Dur, Mr. Michael R. Holly, and Mr. Robert G. Isaman each retired from the Board of Directors to become consultants to the Company. In addition, Mr. Richard S. McGowan was appointed Chairman of the Board.

Last week, TechPrecision announced that it will release financial results for its 2017 fiscal Q4 and year end on June 28, 2017. It will hold a conference call at 4:30 p.m. Eastern (U.S.) time on June 28, 2017.

TechPrecision Corp. (TPCS), closed Thursday's trading session at $0.67, up 0.74%, on 12,500 volume with 10 trades. The average volume for the last 60 days is 34,705 and the stock's 52-week low/high is $0.21/$0.99.

Heritage Global, Inc. (HGBL)

SmallCapVoice and TheMicrocapNews reported previously on Heritage Global, Inc. (HGBL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Heritage Global, Inc. is a leader in asset liquidation transactions, valuations, and advisory services. The Company concentrates on identifying, valuing, acquiring, and monetizing underlying assets in 28 international manufacturing and technology sectors. Heritage Global’s operating companies are Heritage Equity Partners, Heritage Global Partners, Heritage Global Valuations, Heritage NLEX, and Heritage Zetabid Realty Services. OTCQB-listed, Heritage Global is based in San Diego, California.

The Company’s aim is to conduct all of its business under its two principal platforms: Heritage Global Partners for auctions, valuations, acquisitions and dispositions of surplus assets and plant closures, and Heritage Equity Partners (HEP) for advisory services and disposition services of distressed and non-distressed continuing enterprise sales. Heritage Equity Partners (HEP), formerly “Equity Partners,” is headquartered in Easton, Maryland. HEP provides boutique investment banking services for special situations.

Heritage Global specializes in acting as an adviser and acquiring or brokering turnkey manufacturing facilities, surplus industrial machinery and equipment, industrial inventories, accounts receivable (AR) portfolios and related intellectual property (IP), and whole business enterprises. The Company has completed hundreds of transactions since establishing, acting as principal and advisor and member of different syndicates together with distressed and surplus asset industry leaders.

Heritage Global has launched Heritage Global Capital (HGC). This is its fixed asset financing services division. HGC complements and expands the Company’s existing asset valuation, advisory, and auction capabilities through adding new service offerings focusing on providing term loans and leases secured by equipment and real estate.

Heritage Global has launched Heritage Zetabid Realty Services (HZRS). This is its real estate auction platform and services division. HZRS complements and expands Heritage Global’s existing asset valuation, advisory, and auction capabilities through adding new service offerings and experienced industry professionals to effectively market and monetize clients’ commercial, industrial, and luxury/bank-owned residential real estate assets. Heritage Zetabid Realty Services is a strategic alliance between Heritage Global and Zetabid, a foremost provider of real estate marketing services.

Last week, Heritage Zetabid Realty & Auction Services, a division of Heritage Global, announced the sale at public auction of six apartments in the Continental Park building located at 87-10 51st Avenue in Elmhurst, New York. The cooperative building is a private gated community with a verdant garden in a park-setting, which has recently gone through an extensive renovation. It features sun-filled, spacious apartments and modern amenities. The live auction will be held at 5:00 p.m. on June 26, 2017 in the community room of the building.

Today, Heritage Global Patents and Trademarks (HGPT) announced it will manage a sealed bid auction for Integrated Drilling Equipment Holdings Corp.’s (IDE) stationary and portable rig apparatus and assembly method patents. IDE was a leader in the engineering, manufacturing, and fabrication of oil and gas rigs. It exited the rig construction business in 2015 to refocus on its core competencies as one of the energy industry’s most respected innovators and providers of power and control solutions. HGPT is a worldwide leader in brokerage and advisory services for intangible assets and a division of Heritage Global Partners, Inc.

Heritage Global, Inc. (HGBL), closed Thursday's trading session at $0.3799, up 14.05%, on 10,732,497 volume with 353 trades. The average volume for the last 60 days is 5,275,529 and the stock's 52-week low/high is $0.0062/$0.142.

Lixte Biotechnology Holdings, Inc. (LIXT)

Real Pennies reported previously on Lixte Biotechnology Holdings, Inc. (LIXT), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings, Inc. is a drug discovery company based in East Setauket, New York. The clinical-stage Company utilizes biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte’s product pipeline encompasses two major categories of compounds at different stages of pre-clinical and clinical development that the Company believes have wide-ranging therapeutic potential for cancer and other debilitating and life-threatening diseases. Lixte Biotechnology lists on the OTC Markets Group’s OTCQB.

The Company’s current drug portfolio includes inhibitors of protein phosphatases, which are important to cell division and DNA damage repair, and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. Lixte’s commitment is to discovering drugs for more effective treatments for cancer. It has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models.

Its unique phosphatase inhibitor is LB-100, its lead compound. LB-100 is in a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three U.S. Oncology Research locations.

Lixte granted an exclusive license of its LB-100 for the treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte Biotechnology Holdings.

Lixte presented a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade in a preclinical model" as a poster (abstract number LB-193) at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC on April 4th. The research was done in collaboration with scientists at the National Institute of Neurological Disorders and Stroke (NINDS), NIH.

Dr. John S. Kovach, Lixte Biotechnology Holdings’ Chief Executive Officer, said, "The study shows that in an animal model Lixte's lead clinical compound, LB-100 has synergistic potential in conjunction with immune checkpoint blockade supporting investigation of its ability to enhance immunotherapy in the clinic. LB-100, a novel, first-in-class, small molecule inhibitor of protein phosphatase 2A (PP2A), recently completed a Phase 1 trial in patients with advanced cancer (Chung 2016). In that trial, LB-100, was well tolerated at doses associated with stabilization of progressive solid tumors in 10 of 21 patients with receiving 2 or more courses of treatment. One patient with previously refractory pancreatic cancer had a partial regression for 11 months."

Lixte Biotechnology Holdings, Inc. (LIXT), closed Thursday's trading session at $0.14, even for the day, on 15,632 volume with 7 trades. The average volume for the last 60 days is 15,655 and the stock's 52-week low/high is $0.085/$0.42.


The QualityStocks
Company Corner


ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.50, up 11.61%, on 23,850 volume, with 13 trades. The stock’s average daily volume over the past 60 days is 3,507, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Reports Fourth Consecutive Quarter of Revenue Growth

ProBility Media Corp. Signs Binding Letter of Intent to Acquire W Marketing

ProBility Media Corp. Expands Distribution with New 2017 Electrician Exam Preparation Series

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.024, up 6.67%, on 10,732,497 volume with 351 trades. The stock’s average daily volume over the past 60 days is 5,275,529, and its 52-week low/high is $0.0062/$0.142.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Completes $1 Million Funding to Continue its BitCoin Cannabis Payment Solutions Development

NetworkNewsWire Announces Publication Discussing the Use of Digital Currency in the Marijuana Market

SinglePoint Embraces Bitcoin to Solve Cannabis Payments

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.1198, up 13.99%, on 4,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 13,859 and its 52-week low/high is $0.0001/$0.75.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Announces Engagement of Atlanta-Based Broker Dealer Carter, Terry & Company

Algae Dynamics Corp Announces Memorandum Of Understanding With Bonify for Supply of Cannabis, Oil Extraction and Sales

Algae Dynamics Corp Announces Joint Venture With ARA - Avanti Rx Analytics Inc. to Formulate, Manufacture and Sell Products Utilizing Algae, Hemp & Cannabis Oils

Patriot One Technologies, Inc. (PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.6378, up 14.12%, on 15,300 volume with 14 trades. The stock’s average daily volume over the past 60 days is 80,672, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Marks 3-Months of Global PATSCAN Sales with $2.7M in Signed Agreements

Patriot One Appoints Former Senior Counter Terrorism Official John Gillies to Board

Patriot One and SENGEX Accelerate PATSCAN Delivery to U.S. Government Agencies

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.40, up 0.28%, on 91,609 volume with 365 trades. The stock’s average daily volume over the past 60 days is 315,476, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

NetworkNewsWire Announces Editorial Discussing the Potential of Cannabis-Based Therapies for Pain Management


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(RNVAZ) +79.31%


(ICLD) +43.19%


MarketClub Analysis
(ENOC) +41.67%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251